| Date | Title | Description |
| 31.01.2025 | Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Stu... | Prioritizing Revita’s clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1 pivotal study; anticipate midpoint data analysis in Q2 2025 and full pivotal ... |
| 12.03.2024 | UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semagl... | Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control.
The human GLP-1 transgene sequence used in ... |
| 12.03.2024 | UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semagl... | - |
| 12.03.2024 | Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in t... | - |
| 02.02.2024 | Metabolic Disorder-Focused Fractyl Health ‘GUTS’ Out a $110 Million IPO | Fractyl Health contends its metabolic disorder product candidates could offer long-lasting effects not achievable with in-demand weight loss medications, such as Wegovy and Zepbound. It now has $110 million in IPO cash to help build that ca... |
| 17.06.2021 | Fractyl Health collects $100M Series F | Fractyl Health has raised $100 million in a round co-led by Maverick Capital, M28 Capital and Population Health Partners. Based in the Boston area, the company is a developer of therapeutics for metabolic diseases. It plans to use the funds... |
| 16.06.2021 | In private equity, compensation lags for women in senior positions | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
In general, 2020 proved to be a good year for private equity dealmakers.
Even as deal value and v... |
| 16.06.2021 | In private equity, compensation lags for women in senior positions | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content 4 ways CEOs can build a successful cloud strategy From PwC
In general, 2020 proved t... |
| 16.06.2021 | Fractyl Announces Closing of $100 Million Series F Financing to Expand Clinical Development Programs in Type 2 Diabetes | Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the closing of a $100 million Series F financing. The financing was led by ne... |
| 10.08.2020 | Weekly Refresh: Fractyl Raised $55M, Wayfair’s Profitable Q2, and More | Photo: Shutterstock
Indigo Ag raised $360M. The startup combines natural microbiology with tech to make the farming industry more environmentally sustainable. This additional funding brought the total of its Series F raise to $535 million. ... |
| 10.08.2020 | Taiwania Capital leads $55m Series E round in Fractyl Laboratories | Premium
Taiwania Capital Management Corporation has led a $55 million Series E financing round in Fractyl Laboratories Inc., a life sciences company focused on tackling metabolic diseases, according to an announcement.
Continue reading this... |
| 10.08.2020 | Fractyl nets $55M for intestine-resurfacing trial in Type 2 diabetes | Fractyl Laboratories, developers of a minimally invasive procedure to resurface the inner linings of the intestine, has raised $55 million to help complete its pivotal clinical trial in Type 2 diabetes.
The study aims to examine the treatme... |
| 10.08.2020 | Fractyl nets $55M for intestine-resurfacing trial in Type 2 diabetes | Fractyl Laboratories, developers of a minimally invasive procedure to resurface the inner linings of the intestine, has raised $55 million to help complete its pivotal clinical trial in Type 2 diabetes.
Sponsored by Agilent Technologies
How... |
| 07.08.2020 | Fractyl Raises $55M to Test Drug-Free Type 2 Diabetes Treatment | Photo: Shutterstock
Type 2 diabetes was an epidemic plaguing this country long before COVID-19 came on the scene. Those afflicted can lose their eyesight, limbs, and hundreds of thousands of dollars treating the chronic condition with drugs... |
| 06.08.2020 | Fractyl Labs Receives $55M Series E Funding |
LEXINGTON, MA, Fractyl Laboratories has raised $55 million in a series E round.
>> Click here for more funding data on Fractyl Labs
>> To export Fractyl Labs funding data to PDF and Excel, click here
According to MDDI, Fr... |
| 06.08.2020 | Fractyl Raises $55 Million in Series E Financing | LEXINGTON, Mass.--(BUSINESS WIRE)--Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today announced a first close of $55 million in a ... |
| 30.11.2017 | Fractyl Raises $44M Series D Round |
LEXINGTON, MA, Fractyl Laboratories (Fractyl) today announced the completion of a $44 million Series D financing.
>> Click here for more funding data on Fractyl Labs
>> To export Fractyl Labs funding data to PDF and Excel, c... |
| 30.11.2017 | With $44M fundraise, could Fractyl make bariatric surgery the penicillin of our generation? | Fractyl Laboratories was founded in 2010 to take that discovery and run with it. On Thursday, the Lexington, Massachusetts-based company announced it had raised $44 Million in new equity financing. The Series D was led by an undisclosed fir... |
| 30.11.2017 | Fractyl Completes $44M Series D Financing | Fractyl Laboratories Inc., a Lexington, Mass.-based developer of minimally invasive procedural therapy that can reverse metabolic diseases, completed a $44m Series D financing.
The round was led by an undisclosed new investor, joined by new... |
| 30.11.2017 | Term Sheet — Thursday, November 30 | A WILD WEDNESDAY
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Here’s a quick summary of what’s been going on: Bitcoin blew past the $9,000 per coin mark on Sunday. Then, all hell broke loo... |
| 30.11.2017 | Fractyl Labs raises $44 million in Series D to develop a treatment for type 2 diabetes | Fractyl Labs, a Lexington, Massachusetts-based startup developing treatments for diabetes, has raised $44 million in Series D financing from a slew of VC firms, including GV, True Ventures, the IDO Fund, General Catalyst, Bessemer Venture P... |
| 30.11.2017 | Fractyl Completes $44 Million Series D | Fractyl Laboratories Inc. (Fractyl) today announced the completion of a $44 million Series D financing, led by an undisclosed new investor and joined by new investors GV, True Ventures, and the IDO Fund. Returning investors include General ... |
| 04.04.2016 | Peter Thiel firm Mithril Capital Management raises $600M | Promoted
Clinical Care Capacity Planning
Learn how to manage clinical care capacity more efficiently during uncertain times.
SAP
Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R... |
| 01.04.2016 | Peter Thiel’s other fund, Mithril Capital Management, raises $600 million | Peter Thiel is having a good month.
According to a new SEC filing, low-flying Mithril Capital Management, which Thiel co-founded with longtime colleague Ajay Royan in 2012, is out raising its second fund with a $600 million target. Sources ... |
| 19.11.2015 | Fractyl Laboratories Raises $17M in Series C Funding | Fractyl Laboratories, Inc., a Waltham, MA-based company that addresses the underlying biology of metabolic diseases including type 2 diabetes, raised an additional $17m in Series C funding.
The round now totals at $57M. New investor Deerfie... |
| 19.11.2015 | Daily funding roundup - November 19, 2015 | PresenceLearning raised $25M; UrbanClap scored $25M; Cinematique closed $3.5M funding
Touchable video platform Cinematique, announced on Thursday that it has closed $3.5 million in a funding round led by Pumori Capital, an investment adviso... |
| 19.11.2015 | Fractyl Announces Completion of $57 Million Series C Investment | |
| 12.09.2014 | Fractyl raises $40 million in support of ablation-based approach to type 2 diabetes | Medtech funding for the week of September 8, 2014 | Diabetes: Fractyl raises $40M, touts positive early results for ablation-based diabetes therapy September 5, 2014 by Arezu Sarvestani
Massachusetts medical device maker Fractyl announced this week that it raised $40 million in support of it... |
| 05.09.2014 | Diabetes: Fractyl raises $40M, touts positive early results for ablation-based diabetes therapy | Massachusetts medical device maker Fractyl announced this week that it raised $40 million in support of its ablation-based approach to type 2 diabetes, which looks promising in early studies.
The company closed a Series C funding round for ... |
| 05.09.2014 | Funding Roundup - week ending 9/5/14 | MindMixer, FanDuel, Delivery Hero, Hobo Labs, Memorado, AirSig, IndoorAtlas, Snaptee, FreeCharge
Seed stage
Brain training company Memorado raised a $1.3 million seed round from Sunstone Capital and angels, including the founders of Zalando... |
| 04.09.2014 | Fractyl Labs Snares $40M in Series C |
WALTHAM, MA, Fractyl Labs announced that Mithril, a growth-stage investment firm with a global portfolio, led a new $40 million Series C funding round.
>> Click here for more funding data on Fractyl Labs
>> To export Fractyl... |
| 04.09.2014 | Fractyl Laboratories Secures $40M in Series C Funding | Fractyl Laboratories, a Waltham, Mass.-based developer of a device-based endoscopic procedure to treat Type 2 diabetes, secured $40m in Series C funding.
The round was led by Mithril with participation from General Catalyst, Bessemer Ventur... |
| 04.09.2014 | Fractyl Labs Raises $40M Series C To Develop Diabetes Treatments | Fractyl Labs, which develops treatments for diabetes, has raised a $40 million Series C round led by Mithril, with participation from returning investors General Catalyst, Bessemer Venture Partners, and Domain Associates. The new capital wi... |
| 18.11.2013 | The lucky ones: Check out Timmerman’s list of biotech startups funded in 2013 | A big idea
A credible management team
At least $5 million from a first-time financing in 2013
Click through to see the entire list. Here are the most interesting companies from the list.
Biodesy – The company’s technology can monitor struct... |
| - | The lucky ones: Check out Timmerman’s list of biotech startups funded in 2013 | Luke Timmerman at Xconomy crunched the biotech funding numbers for this year to compile a class of 2013 list. You won’t be surprised that he found things haven’t been this bad since 1996:
There were only 102 first-time financings of life sc... |
| - | Peter Thiel firm Mithril Capital Management raises $600M | Mithril Capital Management, the Peter Thiel-backed venture firm that draws its name from Lord of the Rings, is raising $600 million for its second fund, according to a regulatory filing. The firm focuses on growth stage tech – and often lif... |
| - | Fractyl Is on a Mission to Cure Type 2 Diabetes |
Today we are proud to announce our investment in Fractyl, a medical technology company co-founded by Harith Rajagopalan and Jay Caplan. Fractyl is pioneering a procedural therapy that can reverse insulin resistance and resulting metabolic... |
| - | With $44M fundraise, could Fractyl make bariatric surgery the penicillin of our generation? | There’s no shortage of unpleasant surprises in medicine, but every now and then the die roll in humanity’s favor. One recent example: bariatric surgery.
Originally designed for weight loss, experts found gastric bypass procedures unexpected... |
